The NIHR have recently published an article on the STAMPEDE trial which is helping to improve the prognosis and quality of life of those diagnosed with prostate cancer.
This is a research study that’s supported by the NIHR, and has been up and running since 2005, with more than 10,000 men having taken part. 125 UK sites are conducting the research, with local NHS Trusts amongst those 125.
The trial is multi-arm, so compares different treatments amongst the participant group – it is also ‘randomised’, so participants are allocated their treatment at random, reducing any bias in allocation.
The results to date from the trial have also influenced the NHS treatment for men with high risk, locally advanced metastatic prostate cancer. More STAMPEDE related news can be found on their website.
You can read the article here, which contains a testimony from a trial participant whose condition and quality of life have been vastly improved.
Prostate Cancer Research Centre – your chance to influence their next call
New report highlights how NIHR support for clinical research benefits the UK economy and NHS
Cancer and Nutrition NIHR Infrastructure Collaboration
RKEDF – Overview of NIHR, CRNs and NIHR portfolio
Register now to attend the 17th Annual Postgraduate Research Conference – Wednesday 3 December 2025
Portrait Concert featuring BU academic at L’Espace du Son Festival 2025, Brussels
From Clinical Applications to Neuro-Inspired Computation
ECR Funding Open Call: Research Culture & Community Grant – Apply Now
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Horizon Europe Work Programme 2025 Published
Horizon Europe 2025 Work Programme pre-Published
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease